Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02280746
Other study ID # RG 8/2013
Secondary ID
Status Recruiting
Phase N/A
First received October 29, 2014
Last updated October 29, 2014
Start date September 2014
Est. completion date December 2015

Study information

Verified date October 2014
Source Medical University of Warsaw
Contact Anna Piwowarczyk
Phone +48224523309
Email piwowarczyk.ann@gamil.com
Is FDA regulated No
Health authority Poland: Ministry of Science and Higher Education
Study type Interventional

Clinical Trial Summary

BACKGRUOUND: Autism spectrum disorder (ASD) is a common condition. The etiology of ASD remains unknown. Recent studies suggest a link between elimination diets and severity of autistic symptoms. The possible effects of a gluten-free diet (GFD) on symptoms remain unknown.

AIM: The aim of the study is to evaluate the impact of gluten challenge on the autistic symptoms in children with autism spectrum disorders (ASD) and on a gluten-free diet (GFD) in comparison to individuals continuing GFD.

METHODS: 70 children with ASD aged 3-5 and 11/12 remaining on GFD for at least 8 weeks will be randomly assigned to gluten-free and gluten-challenge diet.


Description:

Autism Spectrum Disorder (ASD) is a neurodevelopmental lifelong disorder, significantly impairing the quality of life of patients and their families. The symptoms are thought to result from interaction between genetics and environment. Treatment is multidisciplinary, based on behavioral therapy, education, and sometimes requires specialized care (i.e. genetics) and pharmacotherapy. The lack of consensus about the etiology of ASD directs researchers to define the condition as combination of symptoms, patient's history data, the impact of co-morbidities (including gastrointestinal disorders), and the effectiveness of various management therapies.

The use of complementary and alternative methods (CAM) of treatment is common and includes especially elimination diets, which are intended to minimize symptoms. The basis for the potentially beneficial impact of dietary intervention has been reported in connection to the correlation between congenital metabolic disorders (phenylketonuria) in patients with ASD and improvements in their overt symptoms in patients with schizophrenia Excessive activity of peptides derived from the metabolism of gluten and casein in individuals with ASD is thought to result in impaired neurotransmission in the brain. The increased permeability of the intestinal barrier, resulting from the inflammatory response (the theory of "leaky gut") in ASD patients, simultaneously promotes excessive absorption of those compounds. Another hypothesis assumes the effectiveness of elimination diets in children with ASD, suggesting allergic background of neuropsychiatric symptoms. Additionally it is emphasized that the lack of ability to communicate symptoms or atypical clinical manifestations (i.e. neuropsychiatric symptoms like hyperactivity, sleep disorders) in children with ASD can make the diagnosis of gastrointestinal symptoms, allergy and other symptoms particularly difficult. Moreover the pain or discomfort may increase the risk of behavioral symptoms.

Review of the literature concerning the effectiveness of gluten-free and casein-free diet (GFCFD) in individuals with ASD reveals a possible bias of the available studies and lack of a definite conclusion. Among 35 identified studies only two randomized controlled trials have been analyzed. The data/information on reported effectiveness of interventions in the behavioral symptoms [mean difference (MD-mean difference) -5.60, 95% CI -9.02 to -2.18, p = 0.001] in Knivsberg's study, is not reliable because of study limitations. Whiteley et al summarized in 2012 the positive effect of GFCFD on various symptoms in ASD patients. However the influence of GFCFD in ASD children can be defined mostly as suggestive because of the methodological limitations. The main biases include: small sample size, unclear process of randomization and allocation, use of different ASD assessment tools, short trial duration, lack of evaluation of patients' compliance to intervention, and other limitations.

The theory of excessive activity of exogenous opioids reports on specific allergies (gluten and casein) suggesting a connection with celiac disease (CD) in subjects with ASD and thus providing a rationale to determine the effect of gluten on gastrointestinal symptoms and consequently on potential behavioral changes in this group of patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 3 Years to 6 Years
Eligibility Inclusion Criteria:

- Children aged 3-5 and 11/12 years with a diagnosis of ASD

- GFD for at least 8 weeks prior to enrollment

- Minimal scores of 15 on SCQ

- Minimal scores 70 points on Leiter scale

- Consent of caregivers to participate in the study

Exclusion Criteria:

- Gluten-mediated disease (celiac disease, wheat allergy)

- Lack of motivation / opportunity to follow a diet

- Malnutrition (defined according World Health Organization - WHO standards as weight for height <-2 SDS - Standard Deviation Scores)

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Gluten challenge
Intervention will be continued for at least 6 months

Locations

Country Name City State
Poland Medical University of Warsaw Warsaw

Sponsors (2)

Lead Sponsor Collaborator
Medical University of Warsaw Nutricia Foundation

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary The extent of autistic symptoms based on the Autism Diagnostic Observation Schedule - 2 (ADOS-2) Change over time - 6 months No
Secondary The severity of symptoms based on a Social Communication Questionnaire (SCQ) Change over time - 6 months No
Secondary Presentation of gastrointestinal (GI) functional disorders (evaluation based on a parent-report form - Rome III diagnostic questionnaire Before, after 12 weeks and at the end of intervention No
Secondary The extent of adaptive level of functioning on Vineland Adaptive Behavior Scale (VABS) Change over time - 6 months No
Secondary The extent of functioning on Autism Spectrum Rating Scale (ASRS) Change over time - 6 months No
Secondary Anthropometry Weight, height based on WHO growth charts, comparison of a ratio of weight for height (WfH), and body mass index (BMI) Change over time - 6 months No
Secondary Intelligence test Leiter International Performance Scale Change over time - 6 months No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02625116 - ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
Not yet recruiting NCT06381856 - Improving Participation of Autistic Children and Adolescents in the Habilitation Process
Completed NCT01945957 - Brain Imaging of Intranasal Oxytocin Treatment in Autism Phase 1
Completed NCT01661855 - A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD Phase 2
Completed NCT01694667 - Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder Phase 2
Completed NCT01691066 - Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder N/A
Completed NCT01592747 - Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine Phase 2
Completed NCT01780090 - Handheld Technology for Speech Development in Students With Autism N/A
Active, not recruiting NCT01417026 - Intranasal Oxytocin and Learning in Autism Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT01695200 - Omega-3 Fatty Acids in Autism Spectrum Disorders Phase 4
Completed NCT02300597 - Internet-based Support for Young People With ADHD and Autism - a Controlled Study N/A
Not yet recruiting NCT00695812 - The Development of Younger Siblings of Children With Autism Now at 10 Years of Age N/A
Completed NCT01675414 - Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD) N/A
Recruiting NCT05910502 - Project AFECT (Autism Family Empowerment Coaching and Training Program) N/A
Completed NCT02081027 - Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Early Phase 1
Completed NCT02797379 - The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders N/A
Terminated NCT01730079 - Near Infrared Spectroscopy in Children With Autism and ADHD
Completed NCT01603225 - Transcranial Direct Current Stimulation and Autism
Completed NCT01931033 - An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders N/A